Foghorn Therapeutics (FHTX) Set to Announce Earnings on Wednesday

Posted by Stanley Muller on Oct 28th, 2026

Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) is projected to announce its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.23) per share and revenue of $6.39 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 2, 2026 at 9:30 AM ET.

Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.14. The firm had revenue of $16.07 million during the quarter, compared to analysts’ expectations of $6.80 million. On average, analysts expect Foghorn Therapeutics to post ($0.86) EPS for the current fiscal year and ($0.91) EPS for the next fiscal year.

Foghorn Therapeutics Stock Performance

FHTX stock opened at $2.05 on Wednesday. Foghorn Therapeutics has a 52-week low of $1.79 and a 52-week high of $7.61. The company’s 50 day simple moving average is $3.89 and its 200-day simple moving average is $4.78.

Analyst Ratings Changes

Several analysts have issued reports on FHTX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Foghorn Therapeutics in a research note on Thursday, October 15th. Citigroup lowered Foghorn Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Thursday, October 1st. Wedbush downgraded Foghorn Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $10.00 to $2.00 in a research note on Friday, October 2nd. HC Wainwright decreased their price objective on Foghorn Therapeutics from $13.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, October 2nd. Finally, Wall Street Zen raised Foghorn Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Four research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $6.14.

View Our Latest Analysis on FHTX

Foghorn Therapeutics Company Profile

(Get Free Report)

Foghorn Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines that target the chromatin regulatory system, which controls how DNA is packaged and how genes are expressed. The company’s research is directed primarily toward cancer therapies, particularly for tumors driven by abnormalities in chromatin-remodeling proteins.

Foghorn uses its proprietary Gene Traffic Control platform to identify and develop small-molecule treatments designed to modulate chromatin-regulating complexes.